Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leprosy

ClinicalTrials.gov lists 52 trials for Leprosy or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 3.

MeSH D007918 Infections C01 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 6 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 8 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 3 Phase 4 Phase 4 4 Not applicable Not applicable 18 Observational Observational 9 Phase 1 Phase 1 6 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 8 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 3 Phase 4 Phase 4 4 Not applicable Not applicable 18 Observational Observational 9

Trials per phase

1 more section with rows

51 of the 52 trials are tagged with Leprosy itself; the rest are tagged with a narrower condition beneath it.

Get the Leprosy report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leprosy trials start? (17)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 6

2002: 1 trials (Phase 2 1) 2006: 5 trials (Observational 2, Not applicable 3) 2007: 2 trials (Phase 4 1, Phase 1 1) 2010: 6 trials (Phase 4 2, Phase 2/3 1, Phase 2 3) 2013: 2 trials (Not applicable 1, Phase 1/2 1) 2014: 1 trials (Not applicable 1) 2015: 1 trials (Phase 4 1) 2017: 5 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 1 1) 2018: 4 trials (Observational 1, Phase 2 2, Phase 1 1) 2019: 3 trials (Not applicable 1, Phase 3 1, Phase 1 1) 2020: 2 trials (Observational 1, Not applicable 1) 2021: 2 trials (Not applicable 2) 2022: 2 trials (Phase 2 2) 2023: 2 trials (Not applicable 1, Phase 3 1) 2024: 4 trials (Observational 2, Not applicable 1, Phase 1/2 1) 2025: 5 trials (Not applicable 4, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 3
2025 5
2024 4
2023 2
2022 2
2021 2
2020 2
2019 3
2018 4
2017 5

Showing 10 of 17 earlier years.

Start your 14-day trial Email me all 17 earlier years as a PDF

No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leprosy trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 6
Phase 1/2 2
Phase 2 8
Phase 2/3 1
Phase 3 3
Phase 4 4
Not applicable 18
Observational 9
Expanded access 1

How many Leprosy trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 4
Recruiting 6
Active, not recruiting 1
Completed 29
Terminated 2

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leprosy trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 3
Lo-Sheng Sanatorium 2
Caja Costarricense de Seguro Social 1

Which drugs are being tested for Leprosy? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PREDNISOLONE 4
Dapsone 3
Bedaquiline 2
Clofazimine 2

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cyclosporine 0.05% 4
MLSA-LAM 2
LEP-F1 + GLA-SE 2
MLCwA 2
Rifampicin 2

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leprosy trials report? (4)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Appendicitis 1 1
Cerebral haemorrhage 1 1
Diabetic metabolic decompensation 1 1
Foetal death 1 1

Which publications cover Leprosy? (85)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Clinical, therapeutic, and stigma-related challenges in leprosy and the emerging role of apremilast in managing leprosy reactions. Travel medicine and infectious disease 2025 Yes
Post-exposure prophylaxis in leprosy (PEOPLE): a cluster randomised trial. The Lancet. Global health 2024 Yes
Safety of single-dose bedaquiline combined with rifampicin for leprosy post-exposure prophylaxis: A Phase 2 randomized non-inferiority trial in the Comoros Islands. PLoS medicine 2024 Yes
Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts. BMC infectious diseases 2023 Yes
Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet. Microbe 2022 Yes

Showing 5 of 85 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Leprosy Annual incidence 1-9 / 100 000 Worldwide Not stated Exact
Leprosy Point prevalence Unknown Worldwide Not stated Unspecified
Leprosy Point prevalence Unknown Worldwide Not stated Exact
Leprosy Annual incidence 1-9 / 100 000 Worldwide Not stated Exact
Leprosy Annual incidence 1-9 / 100 000 Worldwide Not stated Unspecified

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Leprosy 548 Exact Orphadata Science knowledge files, Product 1
Leprosy 548 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages